Summary
Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H1 2016’, provides an overview of the H1N1 Infection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for H1N1 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H1N1 Infection and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
- The report reviews pipeline therapeutics for H1N1 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved H1N1 Infection therapeutics and enlists all their major and minor projects
- The report assesses H1N1 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for H1N1 Infection
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
CEL-SCI Corporation
Cilian AG
CSL Limited
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
MedImmune, LLC
Microbiotix, Inc.
Mucosis B.V.
NanoViricides, Inc.
NewLink Genetics Corporation
Novavax, Inc.
OPKO Health, Inc.
PeptiDream Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Theraclone Sciences, Inc.
Touchlight Genetics Limited
United Therapeutics Corporation
Vaxart, Inc.
Vironova AB
Visterra, Inc.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
H1N1 Infection Overview 9
Therapeutics Development 10
Pipeline Products for H1N1 Infection – Overview 10
Pipeline Products for H1N1 Infection – Comparative Analysis 11
H1N1 Infection – Therapeutics under Development by Companies 12
H1N1 Infection – Therapeutics under Investigation by Universities/Institutes 16
H1N1 Infection – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
H1N1 Infection – Products under Development by Companies 20
H1N1 Infection – Products under Investigation by Universities/Institutes 23
H1N1 Infection – Companies Involved in Therapeutics Development 24
Adamas Pharmaceuticals, Inc. 24
Akshaya Bio Inc. 25
Altimmune, Inc. 26
Antigen Express, Inc. 27
Beijing Minhai Biotechnology Co., Ltd 28
CEL-SCI Corporation 29
Cilian AG 30
CSL Limited 31
EpiVax, Inc. 32
Etubics Corporation 33
Gemmus Pharma Inc. 34
iBio, Inc. 35
ILiAD Biotechnologies, LLC 36
Inovio Pharmaceuticals, Inc. 37
Johnson & Johnson 38
Kineta, Inc. 39
Kyowa Hakko Kirin Co., Ltd. 40
Medicago Inc. 41
MedImmune, LLC 42
Microbiotix, Inc. 43
Mucosis B.V. 44
NanoViricides, Inc. 45
NewLink Genetics Corporation 46
Novavax, Inc. 47
OPKO Health, Inc. 48
PeptiDream Inc. 49
Sarepta Therapeutics, Inc. 50
Sirnaomics, Inc. 51
Takeda Pharmaceutical Company Limited 52
TechnoVax, Inc. 53
Theraclone Sciences, Inc. 54
Touchlight Genetics Limited 55
United Therapeutics Corporation 56
Vaxart, Inc. 57
Vironova AB 58
Visterra, Inc. 59
Zydus Cadila Healthcare Limited 60
H1N1 Infection – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 65
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
A-06 - Drug Profile 71
ADS-324 - Drug Profile 72
AEA-35p - Drug Profile 73
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile 74
Aspidasept - Drug Profile 75
C-05 - Drug Profile 76
CiFlu - Drug Profile 77
CR-9114 - Drug Profile 79
diridavumab - Drug Profile 80
Fludase - Drug Profile 82
FluGEM - Drug Profile 84
FVH-1 - Drug Profile 86
Gamma-Flu - Drug Profile 87
GP-1001 - Drug Profile 88
GP-1681 - Drug Profile 89
GREFLU/CAL - Drug Profile 91
H1N1 [A/Aichi/2/68] vaccine - Drug Profile 92
HB-36.6 - Drug Profile 93
Human Antibody Based Vaccines - Drug Profile 94
iHA-24 - Drug Profile 96
infectious vaccine - Drug Profile 97
Influ-nRNA - Drug Profile 98
influenza [serotype A] vaccine - Drug Profile 99
influenza [strain A/H1N1] vaccine - Drug Profile 100
influenza [strain A/H1N1] vaccine - Drug Profile 102
influenza [strain A/H1N1] vaccine - Drug Profile 103
influenza [strain H1N1] (monovalent) vaccine - Drug Profile 104
influenza [strain H1N1] (mutivalent) vaccine - Drug Profile 105
influenza [strain H1N1] vaccine - Drug Profile 106
influenza [strain H1N1] vaccine - Drug Profile 107
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 108
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 109
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 110
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 111
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 112
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 113
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 115
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 116
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 118
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 120
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 121
influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 122
influenza vaccine - Drug Profile 123
influenza vaccine - Drug Profile 125
INO-3510 - Drug Profile 126
JNJ-872 - Drug Profile 127
LEAPS-H1N1-DC - Drug Profile 129
MBX-2329 - Drug Profile 130
MBX-2546 - Drug Profile 132
NEO-8877 - Drug Profile 133
NVINF-1 - Drug Profile 134
NVINF-2 - Drug Profile 136
pertussis [strain BPZE1] vaccine - Drug Profile 137
PNSIA-28 - Drug Profile 139
PNSIA-49 - Drug Profile 140
radavirsen - Drug Profile 141
Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile 143
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 144
Small Molecules for RSV and Influenza A Infections - Drug Profile 145
Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 146
Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 147
Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile 149
STP-702 - Drug Profile 150
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 151
TCN-032 - Drug Profile 152
TVX-002 - Drug Profile 154
VH-244 - Drug Profile 155
VIS-410 - Drug Profile 157
VNFC-045 - Drug Profile 159
VNFC-051 - Drug Profile 160
VXAA-1.1 - Drug Profile 161
Z-3G1 - Drug Profile 162
H1N1 Infection – Recent Pipeline Updates 163
H1N1 Infection - Dormant Projects 183
H1N1 Infection – Discontinued Products 187
H1N1 Infection – Product Development Milestones 188
Featured News & Press Releases 188
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198
List of Tables
Number of Products under Development for H1N1 Infection, H1 2016 15
Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Products under Development by Companies, H1 2016 25
Products under Development by Companies, H1 2016 (Contd..1) 26
Products under Development by Companies, H1 2016 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2016 28
H1N1 Infection – Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 29
H1N1 Infection – Pipeline by Akshaya Bio Inc., H1 2016 30
H1N1 Infection – Pipeline by Altimmune, Inc., H1 2016 31
H1N1 Infection – Pipeline by Antigen Express, Inc., H1 2016 32
H1N1 Infection – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 33
H1N1 Infection – Pipeline by CEL-SCI Corporation, H1 2016 34
H1N1 Infection – Pipeline by Cilian AG, H1 2016 35
H1N1 Infection – Pipeline by CSL Limited, H1 2016 36
H1N1 Infection – Pipeline by EpiVax, Inc., H1 2016 37
H1N1 Infection – Pipeline by Etubics Corporation, H1 2016 38
H1N1 Infection – Pipeline by Gemmus Pharma Inc., H1 2016 39
H1N1 Infection – Pipeline by iBio, Inc., H1 2016 40
H1N1 Infection – Pipeline by ILiAD Biotechnologies, LLC, H1 2016 41
H1N1 Infection – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 42
H1N1 Infection – Pipeline by Johnson & Johnson, H1 2016 43
H1N1 Infection – Pipeline by Kineta, Inc., H1 2016 44
H1N1 Infection – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 45
H1N1 Infection – Pipeline by Medicago Inc., H1 2016 46
H1N1 Infection – Pipeline by MedImmune, LLC, H1 2016 47
H1N1 Infection – Pipeline by Microbiotix, Inc., H1 2016 48
H1N1 Infection – Pipeline by Mucosis B.V., H1 2016 49
H1N1 Infection – Pipeline by NanoViricides, Inc., H1 2016 50
H1N1 Infection – Pipeline by NewLink Genetics Corporation, H1 2016 51
H1N1 Infection – Pipeline by Novavax, Inc., H1 2016 52
H1N1 Infection – Pipeline by OPKO Health, Inc., H1 2016 53
H1N1 Infection – Pipeline by PeptiDream Inc., H1 2016 54
H1N1 Infection – Pipeline by Sarepta Therapeutics, Inc., H1 2016 55
H1N1 Infection – Pipeline by Sirnaomics, Inc., H1 2016 56
H1N1 Infection – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 57
H1N1 Infection – Pipeline by TechnoVax, Inc., H1 2016 58
H1N1 Infection – Pipeline by Theraclone Sciences, Inc., H1 2016 59
H1N1 Infection – Pipeline by Touchlight Genetics Limited, H1 2016 60
H1N1 Infection – Pipeline by United Therapeutics Corporation, H1 2016 61
H1N1 Infection – Pipeline by Vaxart, Inc., H1 2016 62
H1N1 Infection – Pipeline by Vironova AB, H1 2016 63
H1N1 Infection – Pipeline by Visterra, Inc., H1 2016 64
H1N1 Infection – Pipeline by Zydus Cadila Healthcare Limited, H1 2016 65
Assessment by Monotherapy Products, H1 2016 66
Assessment by Combination Products, H1 2016 67
Number of Products by Stage and Target, H1 2016 69
Number of Products by Stage and Mechanism of Action, H1 2016 71
Number of Products by Stage and Route of Administration, H1 2016 73
Number of Products by Stage and Molecule Type, H1 2016 75
H1N1 Infection Therapeutics – Recent Pipeline Updates, H1 2016 168
H1N1 Infection – Dormant Projects, H1 2016 188
H1N1 Infection – Dormant Projects (Contd..1), H1 2016 189
H1N1 Infection – Dormant Projects (Contd..2), H1 2016 190
H1N1 Infection – Dormant Projects (Contd..3), H1 2016 191
H1N1 Infection – Discontinued Products, H1 2016 192
List of Figures
Number of Products under Development for H1N1 Infection, H1 2016 15
Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Products, H1 2016 24
Assessment by Monotherapy Products, H1 2016 66
Assessment by Combination Products, H1 2016 67
Number of Products by Top 10 Targets, H1 2016 68
Number of Products by Stage and Top 10 Targets, H1 2016 68
Number of Products by Top 10 Mechanism of Actions, H1 2016 70
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 70
Number of Products by Routes of Administration, H1 2016 72
Number of Products by Stage and Routes of Administration, H1 2016 72
Number of Products by Top 10 Molecule Types, H1 2016 74
Number of Products by Stage and Top 10 Molecule Types, H1 2016 74
